PE70698A1 - CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA - Google Patents

CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA

Info

Publication number
PE70698A1
PE70698A1 PE1997000351A PE00035197A PE70698A1 PE 70698 A1 PE70698 A1 PE 70698A1 PE 1997000351 A PE1997000351 A PE 1997000351A PE 00035197 A PE00035197 A PE 00035197A PE 70698 A1 PE70698 A1 PE 70698A1
Authority
PE
Peru
Prior art keywords
protein
moles
igg
tnfo
asthma
Prior art date
Application number
PE1997000351A
Other languages
Spanish (es)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE70698A1 publication Critical patent/PE70698A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UNA PROTEINA CARACTERIZADA PORQUE LA PORCION SOLUBLE DE LA PROTEINA RECEPTORA DE TNF p55 SE ENCUENTRA UNIDA A UNA INMUNOGLOBULINA G (IgG), DE PREFERENCIA G1 HUMANA, EN DONDE DICHA IgG FUSIONADA CONTIENE TODOS LOS DOMINIOS DE LA IgG, EXCEPTO EL PRIMER DOMINIO DE IgG DE LA REGION CONSTANTE DE LA CADENA PESADA DE LA IgG. TAMBIEN SE REFIERE A LAS PREPARACIONES PURIFICADAS DEL TNFR-Ig, EXPRESADOS A PARTIR DE CULTIVOS QUE PRODUCEN LA PROTEINA, LA QUE ADEMAS ESTA UNIDA A OLIGOSACARIDOS QUE TERMINAN EN UNO O MAS RESIDUOS DE ACIDO SIALICO Y N-ACETILGLUCOSAMINA, EN DONDE DICHAS PREPARACIONES PURIFICADAS COMPRENDEN PROPORCIONES ESPECIFICAS DE: (a) ACIDO SIALICO, EN UNA RELACION MOLAR CON RESPECTO A LA PROTEINA DE 4 MOLES A 7 MOLES, Y (b) N-ACETIL-GLUCOSAMINA, EN UNA RELACION MOLAR CON RESPECTO A LA PROTEINA DE 1 MOL A 2 MOLES, ADEMAS PRESENTAN UN PUNTO ISOELECTRICO DE 5,5 A 7,5. LAS PROTEINAS DE FUSION DEL RECEPTOR DEL FACTOR DE NECROSIS TUMORAL (TNF) E IgG1, SOLUBLE RECOMBINANTE (TNFR-Ig) ACTUAN BLOQUEANDO LA ACCION DEL TNFO, SIENDO UTILES PARA ALIVIAR EL ASMAIT REFERS TO A PROTEIN CHARACTERIZED BECAUSE THE SOLUBLE PORTION OF THE TNF RECEPTOR PROTEIN p55 IS LINKED TO AN IMMUNOGLOBULIN G (IgG), WHERE SUCH FUSED IgG CONTAINS ALL THE DOMAINS OF THE FIRST OF THE CONSTANT REGION OF THE HEAVY CHAIN OF THE IgG. IT ALSO REFERS TO THE PURIFIED PREPARATIONS OF TNFR-Ig, EXPRESSED FROM CROPS THAT PRODUCE PROTEIN, WHICH ALSO IS LINKED TO OLIGOSACCHARIDES THAT END IN ONE OR MORE RESIDUES OF SALIC ACID AND N-ACETILGLUCOSAMINE, WHERE IN WHICH THEY ARE PRESIDIFIED SPECIFIC PROPORTIONS OF: (a) SIALIC ACID, IN A MOLAR RELATION WITH RESPECT TO THE PROTEIN OF 4 MOLES TO 7 MOLES, AND (b) N-ACETYL-GLUCOSAMINE, IN A MOLAR RELATION WITH RESPECT TO THE PROTEIN OF 1 MOL TO 2 MOLES, ALSO PRESENT AN ISOELECTRIC POINT OF 5.5 TO 7.5. THE TUMOR NECROSIS FACTOR RECEPTOR FUSION PROTEINS (TNF) AND IgG1, SOLUBLE RECOMBINANT (TNFR-Ig) ACT BY BLOCKING THE ACTION OF TNFO, BEING USEFUL TO RELIEF ASTHMA

PE1997000351A 1996-05-08 1997-05-05 CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA PE70698A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
PE70698A1 true PE70698A1 (en) 1998-11-18

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000351A PE70698A1 (en) 1996-05-08 1997-05-05 CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA

Country Status (15)

Country Link
EP (1) EP0910413A2 (en)
JP (1) JP2000510113A (en)
KR (1) KR20000010825A (en)
CN (1) CN1233189A (en)
AR (1) AR007020A1 (en)
AU (1) AU725408B2 (en)
BR (1) BR9708928A (en)
CA (1) CA2253557A1 (en)
CO (1) CO4820397A1 (en)
HR (1) HRP970224A2 (en)
MA (1) MA24169A1 (en)
PE (1) PE70698A1 (en)
TR (1) TR199802238T2 (en)
WO (1) WO1997041895A2 (en)
ZA (1) ZA973843B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2316545A1 (en) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (en) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
ES2304602T3 (en) * 2003-02-28 2008-10-16 Ares Trading S.A. LIQUID FORMULATIONS OF THE UNION PROTEIN TO THE TBP-1 TUMOR NECROSIS FACTOR.
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (en) 2006-10-20 2009-08-12 Biogen Idec Inc Treatment of demyelinating disorders.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (en) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
BR9508419A (en) * 1994-07-22 1997-11-18 Hoffmann La Roche Pharmaceutical compositions comprising a cholinergic tnf binding protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
BR9708928A (en) 2000-05-09
MA24169A1 (en) 1997-12-31
CO4820397A1 (en) 1999-07-28
KR20000010825A (en) 2000-02-25
EP0910413A2 (en) 1999-04-28
CN1233189A (en) 1999-10-27
AR007020A1 (en) 1999-10-13
TR199802238T2 (en) 1999-02-22
HRP970224A2 (en) 1998-04-30
AU2776497A (en) 1997-11-26
ZA973843B (en) 1997-11-10
AU725408B2 (en) 2000-10-12
WO1997041895A2 (en) 1997-11-13
JP2000510113A (en) 2000-08-08
WO1997041895A3 (en) 1998-03-12
CA2253557A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
Beck et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells
UY25897A1 (en) PREPARATION OF FUSION PROTEINS WITH PORTIONS OF IMMUNOGLOBULINS
DE69227041D1 (en) EXPRESSION AND CLEANING OF RECOMBINANT, SOLUBLE TISSUE FACTOR
ATE168415T1 (en) WATER SOLUBLE PEPTIDE ANALOGUES WITH BINDING SITES
SE9100799D0 (en) RECOMBINANT HUMAN FACTOR VIII DERIVATIVES
SE8904239L (en) A RECOMBINATE, HUMAN FACTOR VIII DERIVATE
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
AU8159394A (en) Immunoconjugates
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
ATE168719T1 (en) OSTEOGENIC PEPTIDES
PE70698A1 (en) CHEMICAL PROTEIN OF UNION TO TNFO FOR THE TREATMENT OF ASTHMA
DK0871474T3 (en) Human insulin generation
RU93045577A (en) MULTIPLE POLYPEPTIDES
DE69030937D1 (en) Interleukin-3 mutants
DE69317886D1 (en) NEW PROPOXYPHENE DERIVATIVES AND THEIR PROTEIN AND POLYPEPTIDE LABELS AND CONJUGATES
PT833917E (en) POLYPEPTIDIC MOLECULES OF THE PRE-ERYTHROCITARY STAGE OF MALARIA
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
NO20011263D0 (en) Moraxella Catarrhalis BASBO34 polypeptides and uses thereof
ATE317851T1 (en) POLYPEPTIDES WITH AMINO ACID SEQUENCES FROM THE N-TERMINAL AREA OF GP116 OF CYTOMEGALOVIRUS AND THEIR USE IN DIAGNOSTICS, PROPHYLAXIS AND THERAPY
Wines et al. The Fab/c fragment of IgG produced by cleavage at cyanocysteine residues
ES2158235T3 (en) ANTIGENIC PEPTIDES WITH SUBSTITUTIONS OF GLYCINE.
HUP0001579A2 (en) Cell surface molecule mediating cell adhesion and signal transmission
IT1262550B (en) Immunotoxins containing purified RIP proteins from Saponaria ocymoides and Vaccaria pyramidata

Legal Events

Date Code Title Description
FD Application declared void or lapsed